# Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

> **NCT05016882** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 698 (actual)

## Conditions studied

- Non-alcoholic Steatohepatitis

## Interventions

- **DRUG:** NNC0194 0499 50 mg/mL
- **DRUG:** Placebo (NNC0194-0499)
- **DRUG:** Semaglutide 3 mg/mL
- **DRUG:** Semaglutide placebo
- **DRUG:** NNC0174 0833 10 mg/mL
- **DRUG:** NNC0174 0833 placebo

## Key facts

- **NCT ID:** NCT05016882
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-31
- **Primary completion:** 2024-12-17
- **Final completion:** 2025-03-14
- **Target enrollment:** 698 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05016882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05016882, "Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05016882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*